Investors in Walgreens Boots Alliance, Inc. Should Contact Levi & Korsinsky Before March 31, 2025 to Discuss Your Rights - WBA — Neutral
WBA Accesswire — February 26, 2025NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Walgreens Boots Alliance, Inc. (NASDAQ:WBA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/walgreens-boots-alliance-inc-lawsuit-submission-form-2?prid=132521&wire=1 or contact Joseph E. Levi, Esq.

HOUSTON--(BUSINESS WIRE)--Stellar Bancorp, Inc. (the “Company”) (NYSE: STEL) announced today that its Board of Directors declared a quarterly cash dividend of $0.14 per share of common stock payable on March 31, 2025, to the shareholders of record at the close of business on March 17, 2025. About Stellar Bancorp, Inc. Stellar Bancorp, Inc. is a bank holding company headquartered in Houston, Texas. The Company's principal banking subsidiary, Stellar Bank, provides a diversified range of commerci.

Salesforce beat on earnings for the quarter but missed on revenue. The company's forecast also fell short of analysts' estimates.

Shares of Tesla ( NASDAQ: TSLA ) fell by -3.97% on Wednesday, compounding shareholders woes after what has been a difficult start to the year.

CNBC's Seema Mody joins 'Closing Bell Overtime' with Salesforce results.

Aris Water Solutions, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides 2025 Outlook; Raises Quarterly Dividend by 33% and Announces Acquisition of the McNeill Ranch — Neutral
ARIS Business Wire — February 26, 2025HOUSTON--(BUSINESS WIRE)--Aris Water Solutions, Inc. (NYSE: ARIS) (“Aris,” “Aris Water” or the “Company”) today announced financial and operating results for the fourth quarter and full year ended December 31, 2024. FOURTH QUARTER AND FULL YEAR 2024 HIGHLIGHTS Grew produced water volumes 7% year-over-year Set a new quarterly record for recycled water volumes, growing 16% for the year and 18% sequentially in the fourth quarter of 2024 Achieved fourth quarter and full year 2024 net income of $13.

Laird Superfood Reports Fourth Quarter and Fiscal Year 2024 Financial Results — Neutral
LSF Business Wire — February 26, 2025BOULDER, Colo.--(BUSINESS WIRE)--Laird Superfood, Inc. (NYSE American: LSF) (“Laird Superfood,” the “Company,” “we,” and “our”), today reported financial results for the fourth quarter and fiscal year ended December 31, 2024. Jason Vieth, Chief Executive Officer, commented, “I am thrilled to share that 2024 was, by far, the best performance for Laird Superfood as a public company. In the last twelve months, we achieved significant growth across our product lines and all sales channels, our high.

VSE Corporation Announces Executive Leadership Appointments Supporting Business Transformation and Growth Strategy — Neutral
VSEC Business Wire — February 26, 2025MIRAMAR, Fla.--(BUSINESS WIRE)--VSE Corporation (“VSE” or the “Company”) (NASDAQ: VSEC), a leading provider of aftermarket distribution and repair services, today announced executive leadership appointments supporting the Company's business transformation to a pure-play aviation aftermarket parts and services provider. Following the recently announced Fleet segment divestiture, these changes are designed to support the Company's future growth and strategic priorities and drive a more streamline.

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress — Neutral
INVA Business Wire — February 26, 2025BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted select corporate progress and achievements. Pavel Raifeld,.

Agilent Reports First-Quarter Fiscal Year 2025 Financial Results — Neutral
A Business Wire — February 26, 2025SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.68 billion for the first quarter ended Jan. 31, 2025, representing growth of 1.4% reported and up 1.2% core(1) compared to the first quarter of 2024. First-quarter GAAP net income was $318 million, or $1.11 per share. This compares with $348 million, or $1.18 per share, in the first quarter of fiscal year 2024. Non-GAAP(2) net income was $377 million, or $1.31 per share during the quarter, com.

GREENWICH, Conn.--(BUSINESS WIRE)--Tiptree Inc. (NASDAQ:TIPT) (“Tiptree” or the “Company”), today announced its financial results for the three months and year ended December 31, 2024. Three Months Ended December 31, Year Ended December 31, ($ in thousands, except per share information) 2024 2023 2024 2023 Total revenues $ 503,599 $ 446,374 $ 2,042,854 $ 1,649,031 Net income (loss) attributable to common stockholders $ 19,553 $ 6,871 $ 53,367 .

Sinclair Reports Fourth Quarter 2024 Financial Results — Neutral
SBGI Business Wire — February 26, 2025BALTIMORE--(BUSINESS WIRE)--Sinclair, Inc. (Nasdaq: SBGI), the "Company" or "Sinclair," today reported financial results for the three and twelve months ended December 31, 2024. Highlights: Comprehensive refinancing substantially completed in early 2025 Fourth quarter Operating Income and other key financial metrics exceeded guidance range Record full-year 2024 political advertising revenues of $405 million, a 16% increase over 2020 levels excluding the Georgia runoff of 2020 Formed EdgeBeam Wi.

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results — Neutral
KURA GlobeNewsWire — February 26, 2025– KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpoint for potential U.S. accelerated approval pathway in frontline intensive chemotherapy trial – – Topline MRD-negative CR results from KOMET-017-IC Phase 3 trial anticipated in 2028 – – Multiple data presentations for ziftomenib and pipeline programs expected throughout 2025 – – $727.4 million in cash, together with anticipated collaboration agreement payments, to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference …

Health Catalyst Reports Fourth Quarter and Year End 2024 Results — Neutral
HCAT GlobeNewsWire — February 26, 2025SALT LAKE CITY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2024.

Ibotta Reports Fourth Quarter and Full Year 2024 Financial Results — Neutral
IBTA Business Wire — February 26, 2025DENVER--(BUSINESS WIRE)--Ibotta, Inc. (NYSE: IBTA), which operates the largest digital promotions network in North America, today announced financial results for the fourth quarter and full year ended December 31, 2024. “2024 was a year of significant growth and change for Ibotta,” said Ibotta CEO and founder, Bryan Leach. “We completed our IPO on the New York Stock Exchange, added Family Dollar, AppCard, Schnucks and Instacart to the IPN, and grew our non-GAAP revenue by 20% all while expandin.

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress — Neutral
RVMD GlobeNewsWire — February 26, 2025Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026 Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancer Company anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of treatment for pancreatic cancer in the second half of 2025 Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif.

Howard Hughes Holdings Inc. Reports Fourth Quarter and Full Year 2024 Results — Neutral
HHH GlobeNewsWire — February 26, 2025THE WOODLANDS, Texas, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Howard Hughes Holdings Inc. (NYSE: HHH) (the “Company,” “HHH,” or “we”) today announced operating results for the fourth quarter and year ended December 31, 2024. The financial statements, exhibits, and reconciliations of non-GAAP measures in the attached Appendix and the Supplemental Information, as available through the Investors section of our website, provide further detail of these results.

scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences — Neutral
SCPH GlobeNewsWire — February 26, 2025BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will present at the following upcoming investor conferences:

Plug Power Corrects Date for Fourth Quarter-Year End 2024 Earnings Call to March 4, 2025 — Neutral
PLUG GlobeNewsWire — February 26, 2025SLINGERLANDS N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, has corrected its upcoming Q4-Year End earnings call to March 4, 2025.

Dorman Products, Inc. Reports Fourth Quarter and Full Year 2024 Results; Issues 2025 Guidance — Neutral
DORM GlobeNewsWire — February 26, 2025Highlights (All comparisons are to the prior year period unless otherwise noted) :
